Bicycle Therapeutics (BCYC) Net Income (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Net Income came in at -$50.3 million in Q2 2026, up 36.24% YoY from -$37.0 million in Q2 2025, and up 17.27% on a QoQ basis from -$60.9 million in Q1 2026.
Analysis
Bicycle Therapeutics (BCYC) Net Income (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Net Income data on file, last reported at -$50.3 million in Q2 2026.
- Quarterly Net Income rose 36.24% year-over-year to -$50.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$142.2 million (up 42.68% YoY) and the FY2025 annual result came in at -$170.8 million, up 2.32% from the prior year.
- Net Income rose to -$50.3 million in Q2 2026, from -$60.9 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $28.1 million in Q4 2025 to a low of -$79.0 million in Q2 2025.
- A 5-year average of -$42.1 million and a median of -$46.1 million in 2023 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 148.66% in 2025, down 129.1% in 2025.
- Tracing BCYC's Net Income over 5 years: stood at -$37.0 million in 2022, then sank by 34.01% to -$49.6 million in 2023, then retreated by 16.31% to -$57.6 million in 2024, then jumped by 148.66% to $28.1 million in 2025, then tumbled by 279.46% to -$50.3 million in 2026.
- The last three Net Income figures came in at -$50.3 million (Q2 2026), -$60.9 million (Q1 2026), and $28.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -50.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.34 Mn |
| Mar 31, 2026 | -60.85 Mn |
| Dec 31, 2025 | 28.05 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.95 Mn |
| Mar 31, 2025 | -60.74 Mn |
| Dec 31, 2024 | -57.65 Mn |
| Sep 30, 2024 | -50.80 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Mar 31, 2024 | -26.51 Mn |
| Dec 31, 2023 | -49.57 Mn |
| Sep 30, 2023 | -49.93 Mn |
| Jun 30, 2023 | -42.60 Mn |
| Mar 31, 2023 | -39.06 Mn |
| Dec 31, 2022 | -36.99 Mn |
| Sep 30, 2022 | -28.35 Mn |
| Jun 30, 2022 | -26.83 Mn |
| Mar 31, 2022 | -27.56 Mn |
| Dec 31, 2021 | -19.06 Mn |
| Sep 30, 2021 | -14.68 Mn |